Skip to main content
SpringerLink
Log in

Chemoprevention of Lung Cancer

  • Chapter
Tumors of the Chest

  • 817 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10.

    Article  PubMed  Google Scholar 

  2. Wingo PA, Reis LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675.

    Article  PubMed  CAS  Google Scholar 

  3. Samet JM. Health benefits of smoking cessation. Clin Chest Med 1991; 12:669.

    PubMed  CAS  Google Scholar 

  4. Samet JM, Wiggins CL, Humble CG, et al. Cigarette smoking and lung cancer in New Mexico. Am Rev Respir Dis 1988; 137:1110.

    CAS  Google Scholar 

  5. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 1999; 17:1794.

    PubMed  CAS  Google Scholar 

  6. Simon GR, Wagner H. Small cell lung cancer. Chest 2003; 123:259S.

    Article  PubMed  Google Scholar 

  7. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618.

    PubMed  CAS  Google Scholar 

  8. Sandier AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003; 30:9.

    Article  CAS  Google Scholar 

  9. Sekido Y, Fong K, Minna J. Cancer of the luna. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott-Raven, 2001; 917.

    Google Scholar 

  10. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 17:1.

    Google Scholar 

  11. Dillman RO, Hemdon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210.

    Article  PubMed  CAS  Google Scholar 

  12. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117:358.

    Article  PubMed  CAS  Google Scholar 

  13. Curran WJ Jr, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000; 19:484a.

    Google Scholar 

  14. Furuse K, Kubota K, Kawahara M, et al. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. J Clin Oncol 1995; 13:869.

    PubMed  CAS  Google Scholar 

  15. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692.

    PubMed  CAS  Google Scholar 

  16. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899.

    Google Scholar 

  17. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36:2699.

    PubMed  CAS  Google Scholar 

  18. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues (retinoids). Fed Proc 1976; 35:1332.

    PubMed  CAS  Google Scholar 

  19. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l study. J Natl Cancer Inst 1998; 90:1371.

    Article  PubMed  CAS  Google Scholar 

  20. Steinbach G, Lynch PM, Phillips RK, et al. The effects of celecoxib, a cyclo-oxygenase inhibitor, in familial adenomatous polyposis. N Eng J Med 2000; 342:1946.

    Article  CAS  Google Scholar 

  21. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315:1501.

    Article  PubMed  CAS  Google Scholar 

  22. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323:795.

    Article  PubMed  CAS  Google Scholar 

  23. Auerbach O, Gere JB, Forman JB, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med 1957; 256:98.

    Article  Google Scholar 

  24. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955–1960 vs. 1970–1977. N Eng J Med 1979; 300:381.

    Article  CAS  Google Scholar 

  25. Auerbach O, Stout AP, Hammond EC, et al. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961; 265:253.

    Article  PubMed  CAS  Google Scholar 

  26. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6:963.

    Article  PubMed  CAS  Google Scholar 

  27. Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts AB, Goodman DS (eds) The Retinoids: Biology, Chemistry and Medicine, 2nd edn. New York: Raven, 1994:443.

    Google Scholar 

  28. Deluca LM. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J 1991; 5:2923.

    Google Scholar 

  29. Lotan R. Retinoids and apoptosis: implication for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87:1655.

    Article  PubMed  CAS  Google Scholar 

  30. Nagy L, Thomazy VA, Heyman RA, et al. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ 1998; 5:11.

    Article  PubMed  CAS  Google Scholar 

  31. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble vitamin A. J Exp Med 1925; 42:597.

    Article  Google Scholar 

  32. Kitareewan S, Pitha-Rowe I, Ma Y, et al. The retinoids and cancer prevention mechanisms. In: Kelloff GJ, Hawk ET, Sigman CC (eds) Cancer Chemoprevention, vol I. Promising Cancer Chemopreventive Agents. Totowa, NJ: Humana (in press)

    Google Scholar 

  33. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334:1561.

    Article  PubMed  CAS  Google Scholar 

  34. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Longterm follow-up. J Natl Cancer Inst 1994; 86:140.

    Article  PubMed  CAS  Google Scholar 

  35. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 11:1216.

    PubMed  CAS  Google Scholar 

  36. Mavne ST, Lippman SM. Retinoids, carotenoids and micronutrients. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th. ed. Philadelphia: Lippincott-Raven, 1997:575.

    Google Scholar 

  37. Krinsky NI. Actions of carotenoids in biologic systems. Annu Rev Nutr 1993; 13:561.

    Article  PubMed  CAS  Google Scholar 

  38. Peto R, Doll R, Buckley JD, et al. Can dietary β-carotene materially reduce human cancer rates? Nature 1981; 290:201.

    Article  PubMed  CAS  Google Scholar 

  39. Floyd RA. Role of free radicals in carcinogenesis and brain ischemia. FASEB J 1990; 4:2587.

    PubMed  CAS  Google Scholar 

  40. Chew BP, Wong TS, Shultz TD, et al. Effects of conjugated dienoic derivatives of linoleic acid and beta-carotene in modulating lymphocyte and macrophage function. Anticancer Res 1997; 17:1099.

    PubMed  CAS  Google Scholar 

  41. Murata T, Tamai H, Morinobu T, et al. Effect of long-term administration of beta-carotene on lymphocyte subsets in humans. Am J Clin Nutr 1994; 60:597.

    PubMed  CAS  Google Scholar 

  42. Toba T, Shidoji Y, Fujii J, et al. Growth suppression and induction of heat-shock protein-70 by 9-cis beta-carotene in cervical dysplasia-derived cells. Life Sci 1997; 61:839.

    Article  PubMed  CAS  Google Scholar 

  43. Muto Y, Fujii J, Shidoji Y, et al. Growth retardation in human cervical dysplasia-derived cell lines by beta-carotene through down-regulation of epidermal growth factor receptor. Am J Clin Nutr 1995; 62(6 suppl):1535S.

    PubMed  CAS  Google Scholar 

  44. Nishino H, Murakoshi M, Ii T, et al. Carotenoids in cancer chemoprevention. Cancer Metastasis Rev 2002; 21:257.

    Article  PubMed  CAS  Google Scholar 

  45. Sies H, Stahl W. Lycopene: antioxidant and biological effects and its bioavailability in the human. Proc Soc Exp Biol Med 1998; 218:121.

    PubMed  CAS  Google Scholar 

  46. Amir H, Karas M, Giat J, et al. Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 1999; 33:105.

    Article  PubMed  CAS  Google Scholar 

  47. Karas M, Amir H, Fishman D, et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 2000; 36:101.

    Article  PubMed  CAS  Google Scholar 

  48. Stahl W, von Laar J, Martin HD, et al. Stimulation of gap junctional communication: comparison of acyclo-retinoic acid and lycopene. Arch Biochem Biophys 2000; 373:271.

    Article  PubMed  CAS  Google Scholar 

  49. Heber D. Colorful cancer prevention: a-carotene, lycopene and lung cancer. Am J Clin Nutr 2000; 72:901.

    PubMed  CAS  Google Scholar 

  50. Mangelsdorf DJ, Umesono K, Evans RM. The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS (eds) The Retinoids: Biology, Chemistry and Medicine, 2nd edn. New York: Raven, 1994:319.

    Google Scholar 

  51. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83:835.

    Article  PubMed  CAS  Google Scholar 

  52. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10:940.

    PubMed  CAS  Google Scholar 

  53. Zelent A, Mendelson C, Kastner P, et al. Differentially expressed isoforms of the mouse retinoic acid receptor beta are generated by usage of two promoters and alternative splicing. EMBO J 1991; 10:71.

    PubMed  CAS  Google Scholar 

  54. Napgal S, Zelent A, Chambon P. RAR-beta-4, a retinoic acid receptor isoform is generated from RAR-beta-2 by alternative splicing and usage of a CUG initiator codon. Proc Natl Acad Sci U S A 1992; 89:2718.

    Article  Google Scholar 

  55. Hu X, Lazar MA. Transcriptional repression by nuclear receptors. Trends Endocrinol Metab 2000; 11:6.

    Article  PubMed  CAS  Google Scholar 

  56. Germain P, Iyer J, Zechel C, et al. Co-regulator recruitment and the mechanism of retinoic acid synergy. Nature 2002; 415:187.

    Article  PubMed  CAS  Google Scholar 

  57. Rachez C, Freedman LP. Mediator complexes and transcription. Curr Opin Cell Biol 2001; 13:274.

    Article  PubMed  CAS  Google Scholar 

  58. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181.

    Article  PubMed  CAS  Google Scholar 

  59. Renaud JP, Rochel N, Ruff M, et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans-retinoic acid. Nature 1995; 378:681.

    Article  PubMed  CAS  Google Scholar 

  60. Davies P, Lippman SM. Biologic basis of retinoid pharmacology: implications for cancer prevention and therapy. Adv Oncol 1996; 12:2.

    Google Scholar 

  61. Lala DS, Mukherjee R, Schulman IG, et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 1996; 383:450.

    Article  PubMed  CAS  Google Scholar 

  62. Mukherjee R, Davies PJ, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386:407.

    Article  PubMed  CAS  Google Scholar 

  63. Perlman T, Evans RM. Nuclear receptors in Sicily: all in the family. Cell 1997; 90:391.

    Article  Google Scholar 

  64. Bischoff ED, Gottardis MM, Moon TE, et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res 1998; 58:479.

    PubMed  CAS  Google Scholar 

  65. Gottardis MM, Bischoff ED, Shirley MA, et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56:5566.

    PubMed  CAS  Google Scholar 

  66. Mariani L, Formelli F, De Palo G, et al. Chemoprevention of breast cancer with fenretinide (4-HPR): study of longterm visual and ophthalmologic tolerability. Tumori 1996; 82:444.

    PubMed  CAS  Google Scholar 

  67. Costa A, Formelli F, Chiesa F, et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994; 54:2032S.

    PubMed  CAS  Google Scholar 

  68. Dimery IW, Hong WK, Lee JJ, et al. Phase I trial of alphatocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 1997; 8:85.

    Article  PubMed  CAS  Google Scholar 

  69. Besa EC, Abrahm JL, Bartholomew MJ, et al. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. Am J Med 1990; 89:739.

    Article  PubMed  CAS  Google Scholar 

  70. Langston AW, Thompson JR, Gudas LJ. Retinoic acid-responsive enhancers located 3 of the Hox A and Hox B homeobox gene clusters. Functional analysis. J Biol Chem 1997; 272:2167.

    Article  PubMed  CAS  Google Scholar 

  71. Clifford JL, Menter DG, Wang M, et al. Retinoid receptor-dependent and-independent effects of N-(4-hydroxyphenyl) retinamide in F9 embryonal carcinoma cells. Cancer Res 1999; 59:14.

    PubMed  CAS  Google Scholar 

  72. Oridate N, Suzuki S, Higuchi M, et al. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997; 89:1191.

    Article  PubMed  CAS  Google Scholar 

  73. Mulshine JL, De Luca LM, Dedrick RL. Regional delivery of retinoids: a new approach to early lung cancer intervention. Clin Biol Basis Lung Cancer Prev 1998; 24:273.

    Google Scholar 

  74. Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97:11280.

    Article  PubMed  CAS  Google Scholar 

  75. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95:681.

    Article  PubMed  CAS  Google Scholar 

  76. Tsuji M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83:493.

    Article  Google Scholar 

  77. Majima M, Isono M, Ikeda Y, et al. Significant roles of inducible cyclooxgenase (COX-2) in angiogenesis in rat. Jpn J Pharmacol 1997; 75:105.

    Article  PubMed  CAS  Google Scholar 

  78. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003; 9:961.

    PubMed  CAS  Google Scholar 

  79. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190:279.

    Article  PubMed  CAS  Google Scholar 

  80. Castonguay A, Rioux N, Duperron C, et al. Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 1998; 24:605.

    Article  PubMed  CAS  Google Scholar 

  81. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58:4997.

    PubMed  CAS  Google Scholar 

  82. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxgenase 2 occurs frequently in human lung cancers, specifically adenocarcinomas. Cancer Res 1998; 58:3761.

    PubMed  CAS  Google Scholar 

  83. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinomas of the lung. Lung Cancer 2000; 30:73.

    Article  PubMed  CAS  Google Scholar 

  84. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7:861.

    PubMed  CAS  Google Scholar 

  85. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002; 9:693.

    PubMed  CAS  Google Scholar 

  86. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and lung cancer in women. Br J Cancer 2002; 87:49.

    Article  PubMed  CAS  Google Scholar 

  87. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19:6584.

    Article  PubMed  CAS  Google Scholar 

  88. Hill BT, Perrin D, Kruczynski A. Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol 2000; 33:7.

    Article  PubMed  CAS  Google Scholar 

  89. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18:927.

    PubMed  CAS  Google Scholar 

  90. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996; 56:2224.

    PubMed  CAS  Google Scholar 

  91. Lantry LE, Zhang Z, Yao R, et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone. Carcinogenesis 2000; 21:113.

    Article  PubMed  CAS  Google Scholar 

  92. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183.

    Article  PubMed  CAS  Google Scholar 

  93. Richardson CM, Sharma RA, Cox KJ, et al. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer 2003; 39:1.

    Article  PubMed  CAS  Google Scholar 

  94. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung cancer carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995; 31:178.

    Article  Google Scholar 

  95. Mukaida H, Toi M, Hirai T, et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991; 68:142.

    Article  PubMed  CAS  Google Scholar 

  96. Neal DE, Mellon K. Epidermal growth factor receptor and bladder cancer: a review. Urol Int 1992; 48:365.

    Article  PubMed  CAS  Google Scholar 

  97. Sainsbury JR, Farndon JR, Needham GK, et al. Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1:1398.

    PubMed  CAS  Google Scholar 

  98. Kurie JM, Shin HJC, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996; 2:1787.

    PubMed  CAS  Google Scholar 

  99. Rusch V, Klimstra D, Linkov I, et al. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res 1995; 55:1365.

    PubMed  CAS  Google Scholar 

  100. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002; 8:54.

    PubMed  CAS  Google Scholar 

  101. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149.

    Article  PubMed  CAS  Google Scholar 

  102. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (Iressa) monotherapy: clinical experience in non-small cell lung cancer. Drug Saf 2004; 27:1081.

    Article  PubMed  CAS  Google Scholar 

  103. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129.

    Article  PubMed  CAS  Google Scholar 

  104. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497.

    Article  PubMed  CAS  Google Scholar 

  105. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Aca Sci U S A 2004; 101:13306.

    Article  CAS  Google Scholar 

  106. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240:889.

    Article  PubMed  CAS  Google Scholar 

  107. Schoonjans K, Martin G, Staels B, et al. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8:159.

    Article  PubMed  CAS  Google Scholar 

  108. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302:93.

    PubMed  CAS  Google Scholar 

  109. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53:409.

    Article  PubMed  CAS  Google Scholar 

  110. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologica 1999; 42:1033.

    Article  CAS  Google Scholar 

  111. Theocharis S, Kanelli H, Politi A, et al. Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histologic type and grade. Lung Cancer 2002; 36:249.

    Article  PubMed  Google Scholar 

  112. Segawa Y, Yoshimura T, Hase T, et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002; 51:108.

    Article  PubMed  CAS  Google Scholar 

  113. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1:465.

    Article  PubMed  CAS  Google Scholar 

  114. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23:100.

    Article  PubMed  CAS  Google Scholar 

  115. Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 2003; 8:45.

    Article  PubMed  Google Scholar 

  116. Lonardo F, Rusch V, Langenfield J, et al. Overexpression of cyclins Dl and E is frequent in bronchial neoplasia and precedes squamous cell carcinoma development. Cancer Res 1999; 59:2470.

    PubMed  CAS  Google Scholar 

  117. Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin Dl proteolysis: a retinoid chemoprevention signal in normal, immortalized and transformed human bronchial epithelial cells. J Natl Cancer Inst 1999; 91:373.

    Article  PubMed  CAS  Google Scholar 

  118. Witschi H, Espiritu I, Suffia M, et al. Expression of cyclin Dl/2 in the lungs of strain A/J mice fed chemopreventive agents. Carcinogenesis 2002; 23:289.

    Article  PubMed  CAS  Google Scholar 

  119. Papadimitrakopoulou VA, Izzo J, Mao L, et al. Cyclin Dl and pl6 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 2001; 7:3127.

    PubMed  CAS  Google Scholar 

  120. Engler TA, Furness K, Malhotra S, et al. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo(6,7-a)pyrrolo(3,4-c)carbazoles. Bioorg Med Chem Lett 2003; 13:2261.

    Article  PubMed  CAS  Google Scholar 

  121. Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 2002; 7:451.

    Article  PubMed  CAS  Google Scholar 

  122. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000; 92:1303.

    Article  PubMed  CAS  Google Scholar 

  123. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93:691.

    Article  PubMed  CAS  Google Scholar 

  124. Zochbauer-Muller S, Fong KM, Maitra A, et al. 5 CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001; 61:3581.

    PubMed  CAS  Google Scholar 

  125. Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001; 61:4556.

    PubMed  CAS  Google Scholar 

  126. Kelloff GJ, Boon CW, Crowell JA, et al. Risk biomarkers and current strategies for cancer prevention. J Cell Biochem Suppl 1996; 25:1.

    PubMed  CAS  Google Scholar 

  127. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12:851.

    PubMed  CAS  Google Scholar 

  128. Workshop report. Biomarkers in cancer chemoprevention. In: Miller AB, Bartsch H, Boffeta P, Dragsted L, Vainio H (eds) Biomarkers in Cancer Chemoprevention, no. 154. Lyon, France: IARC Scientific, 2001:1.

    Google Scholar 

  129. Lippman SM, Lee JS, Lotan R, et al. Biomarkers as intermediate endpoints in chemoprevention trials. J Natl Cancer Inst 1990; 82:555.

    Article  PubMed  CAS  Google Scholar 

  130. Srivastava S, Rossi SC. Early detection research program at the NCI. Int J Cancer 1996; 69:35.

    Article  PubMed  CAS  Google Scholar 

  131. Sullivan Pepe M, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93:1054.

    Article  Google Scholar 

  132. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431.

    Article  PubMed  CAS  Google Scholar 

  133. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54:1014.

    Article  PubMed  CAS  Google Scholar 

  134. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95:470.

    Article  PubMed  Google Scholar 

  135. Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene 2002; 21:6870.

    Article  PubMed  CAS  Google Scholar 

  136. Wu X, Zhao H, Suk R, et al. Genetic susceptibility to to-bacco-related cancer. Oncogene 2004; 23:6500.

    Article  PubMed  CAS  Google Scholar 

  137. Alpha-tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 1994; 330:1029.

    Article  Google Scholar 

  138. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150.

    Article  PubMed  CAS  Google Scholar 

  139. Block G, Patterson B, Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992; 18:1.

    Article  PubMed  CAS  Google Scholar 

  140. van Poppel G, Goldbohm RA. Epidemiologic evidence for beta-carotene and cancer prevention. Am J Clin Nutr 1995; 62:1393S.

    PubMed  Google Scholar 

  141. Menkes MS, Comstock GW, Vuilleumier JP, et al. Serum beta-carotene, vitamins A and E, selenium and the risk of lung cancer. N Engl J Med 1986; 315:1250.

    Article  PubMed  CAS  Google Scholar 

  142. Stryker WS, Kaplan LA, Stein EA, et al. The relation of diet, cigarette smoking, and alcohol consumption to plasma beta-carotene and alpha-tocopherol levels. Am J Epidemiol 1988; 127:283.

    PubMed  CAS  Google Scholar 

  143. Greenwald P. Beta-carotene and lung cancer: a lesson for future chemoprevention investigations? J Natl Cancer Inst 2003 Jan 1; 95:E1.

    Article  PubMed  Google Scholar 

  144. Handelman GJ, Packer L, Cross CE. Destruction of tocopherols, carotenoids, and retinol in human plasma by cigarette smoke. Am J Clin Nutr 1996; 63:559.

    PubMed  CAS  Google Scholar 

  145. Stram DO, Wu AH. Re: Beta-carotene and lung cancer: a lesson for future chemoprevention investigations? J Natl Cancer Inst 2003 May 21; 95:E4.

    Article  PubMed  Google Scholar 

  146. Omaye ST, Krinsky NI, Kagan VE, et al. Beta-carotene: friend or foe? Fundam Appl Toxicol 1997; 40:163.

    Article  PubMed  CAS  Google Scholar 

  147. Buiatti E. An overview of recent results of chemoprevention trials. In: Maltoni C, Soffritti M, Davis W (eds) The Scientific Basis of Cancer Chemoprevention. Amsterdam: Elsevier, 1996:257.

    Google Scholar 

  148. Paolini M, Cantelli-Forti G, Perocco P, et al. Co-carcinogenic effect of beta-carotene. Nature 1999; 398:760.

    Article  PubMed  CAS  Google Scholar 

  149. Perocco P, Paolini M, Mazzullo M, et al. Beta-carotene as enhancer of cell transforming activity of powerful carcinogens and cigarette-smoke condensate on BALB/c 3T3 cells in vitro. Mutat Res 1999; 440:83.

    PubMed  CAS  Google Scholar 

  150. Salgo MG, Cueto R, Winston GW, et al. Beta-carotene and its oxidation products have different effects on microsome mediated binding of benzo(a)pyrene to DNA. Free Radic Biol Med 1999; 26:162.

    Article  PubMed  CAS  Google Scholar 

  151. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145.

    Article  PubMed  CAS  Google Scholar 

  152. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12:937.

    PubMed  CAS  Google Scholar 

  153. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl)-retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6:2973.

    PubMed  CAS  Google Scholar 

  154. Arnold AM, Browman GP, Levine MN, et al. The effect of the synthetic retinoid etredinate on sputum cytology: results from a randomized trial. Br J Cancer 1992; 65:737.

    PubMed  CAS  Google Scholar 

  155. McLarty JW, Holiday DB, Girard WM, et al. Beta-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995; 62:1431S.

    PubMed  CAS  Google Scholar 

  156. Heimbuger DC, Alexander CB, Birch, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized double-blind intervention trial. JAMA 1988; 259:1525.

    Article  Google Scholar 

  157. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12:851.

    PubMed  CAS  Google Scholar 

  158. Kurie JM, Lotan R, Lee JS, et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003; 95:206.

    Article  PubMed  CAS  Google Scholar 

  159. Khuri FR, Lotan R, Kemp B, et al. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 2000; 18:2798.

    PubMed  CAS  Google Scholar 

  160. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase II b trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94:1001.

    PubMed  CAS  Google Scholar 

  161. van Zandwijk N, Dalesio O, Pastorino U, et al. EURO-SCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977.

    Article  PubMed  Google Scholar 

  162. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605.

    Article  PubMed  CAS  Google Scholar 

  163. Ravi RK, Scott FM, Cuttitta F, et al. Induction of gastrin-releasing peptide by all-trans retinoic acid in small-cell lung cancer cells. Oncol Rep 1998; 5:497.

    PubMed  CAS  Google Scholar 

  164. Siegfried JM, DeMichele MA, Hunt JD, et al. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells: association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. Am J Respir Crit Care Med 1997; 156:358.

    PubMed  CAS  Google Scholar 

  165. Manna SK, Aggarwal BB. All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappaB, activated protein-1 and apoptosis in human lung cancer cells. Oncogene 2000; 19:2110.

    Article  PubMed  CAS  Google Scholar 

  166. Pei XH, Nakanishi Y, Takayama K, et al. Benzo(a)pyrene activates the human p53 gene through induction of nuclear factor kappaB activity. J Biol Chem 1999; 274:35240.

    Article  PubMed  CAS  Google Scholar 

  167. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res 2001; 61:1457.

    PubMed  CAS  Google Scholar 

  168. Khuri FR, Lee JJ, Lippman SM, et al. Isotretinoin effects on head and neck cancer recurrence and second primary tumors (abstract 359). Proc Am Soc Clin Oncol 2003; 22:90.

    Google Scholar 

  169. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996; 276:1957.

    Article  PubMed  CAS  Google Scholar 

  170. Blot WJ, Li JY, Taylor RR, et al. Linxian nutrition intervention trials: supplementation with specific vitamin/ mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85:1483.

    Article  PubMed  CAS  Google Scholar 

  171. Cohen V, Khuri FR. Chemoprevention of lung cancer: current status and future prospects. Cancer Metastasis Rev 2002; 21:349.

    Article  PubMed  CAS  Google Scholar 

  172. Moon RC, Rao KV, Detrisac CJ, et al. Animal models for chemoprevention of respiratory cancer. J Natl Cancer Inst Monogr 1992; 13:45.

    PubMed  Google Scholar 

  173. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410:1111.

    Article  PubMed  CAS  Google Scholar 

  174. Meuwissen R, Linn SC, van der Valk M, et al. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-ras oncogene. Oncogene 2001; 20:6551.

    Article  PubMed  CAS  Google Scholar 

  175. Meuwissen R, Linn SC, Linnoila I, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rbl in a conditional mouse model. Cancer Cell 2003; 4:181.

    Article  PubMed  CAS  Google Scholar 

  176. Wattenberg LW, Wiedman TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone diproprionate and the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000; 21:179.

    Article  PubMed  CAS  Google Scholar 

  177. Wattenberg LW, Wiedman TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997; 57:5489.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Sir Mortimer B. Davis Jewish General Hospital McGill University School of Medicine, Montreal, QC, Canada

    Victor Cohen

  2. Winship Cancer Institute, Emory University, Atlanta, GA, USA

    Fadlo R. Khuri

Authors
  1. Victor Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fadlo R. Khuri
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos MD, PhD

  2. Royal Marsden NHS Trust Hospitals, London, UK

    Christopher M. Nutting MB BA, MD, FRCR

  3. Evangelismos General Hospital, Athens Medical School, Athens, Greece

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

  4. Faculty of Medicine, McGill University, Montreal, Canada

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Cohen, V., Khuri, F.R. (2006). Chemoprevention of Lung Cancer. In: Syrigos, K.N., Nutting, C.M., Roussos, C. (eds) Tumors of the Chest. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-31040-1_53

Download citation

  • DOI: https://doi.org/10.1007/3-540-31040-1_53

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31039-6

  • Online ISBN: 978-3-540-31040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation